ACADIA Pharmaceuticals Inc. Non Cash Items (Other)

Non Cash Items (Other) of ACAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including Non Cash Items (Other) growth rates and interactive chart.


Highlights and Quick Summary

  • Non Cash Items (Other) for the quarter ending March 30, 2021 was $13 Million (a -37.7% decrease compared to previous quarter)
  • Year-over-year quarterly Non Cash Items (Other) decreased by -31.63%
  • Annual Non Cash Items (Other) for 2020 was $130 Million (a 59.93% increase from previous year)
  • Annual Non Cash Items (Other) for 2019 was $81.3 Million (a -2.66% decrease from previous year)
  • Annual Non Cash Items (Other) for 2018 was $83.5 Million (a 10.53% increase from previous year)
  • Twelve month Non Cash Items (Other) ending March 30, 2021 was $119 Million (a -8.31% decrease compared to previous quarter)
  • Twelve month trailing Non Cash Items (Other) increased by 42.48% year-over-year
Trailing Non Cash Items (Other) for the last four month:
30 Mar '21 30 Dec '20 29 Sep '20 29 Jun '20
$119 Million $130 Million $128 Million $83.6 Million
Visit stockrow.com/ACAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Non Cash Items (Other) of ACADIA Pharmaceuticals Inc.

Most recent Non Cash Items (Other)of ACAD including historical data for past 10 years.

Interactive Chart of Non Cash Items (Other) of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. Non Cash Items (Other) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $13.04
2020 $20.93 $66.14 $19.07 $23.85 $129.98
2019 $19.28 $21.45 $20.43 $20.11 $81.27
2018 $20.34 $21.88 $20.82 $20.45 $83.49
2017 $22.02 $19.7 $18.24 $15.57 $75.54
2016 $14.82 $14.01 $13.88 $11.96 $54.67
2015 $8.66 $9.27 $7.5 $14.53 $39.95
2014 $4.65 $3.9 $4.33 $3.16 $16.04
2013 $2.17 $1.89 $1.06 $0.58 $5.7
2012 $0.55 $0.28 $0.41 $0.43 $1.68
2011 $0.41 $0.4 $1.22 $0.38 $2.4
2010 $0.54 $0.34 $0.2 $1.49

Business Profile of ACADIA Pharmaceuticals Inc.

Sector: Healthcare
Industry: Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.